Budesonide in the treatment of idiopathic intestinal infl ammation
Authors:
Lukáš M.
Authors place of work:
Klinické a výzkumné centrum pro střevní záněty, Klinické centrum ISCARE a. s. a 1. LF UK v Praze
Published in the journal:
Gastroent Hepatol 2020; 74(5): 449-451
Category:
Zdroje
1. Lukáš M, Dušek L. Idiopatické střevní záněty ve statistických ukazatelích a analýzách. In: Lukáš M (ed). Idiopatické střevní záněty. Nové trendy a mezioborové souvislosti. Praha: Grada 2020.
2. Truleove SC, Witts IJ. Cortisone in ulcerative colitis. Final report on therapeutic trial. Br Med J 1955; 2: 1041–1048. doi: 10.1136/bmj.2.4947.1041.
3. Modigliani R, Mary JY,Simon JF et al. Clinical, endoscopic and biological picture of attacks of Crohn’s disease. Gastroenterology 1990; 98: 811–818. doi: 10.1016/0016-5085 (90) 90002-i.
4. Lukáš M. Pokroky v medikamentózní konvenční léčbě. In: Lukáš M (ed). Pokroky v diagnostice a léčbě idiopatických střevních zánětů. Praha: Galen 2019.
5. Rezaie A, Kuenzig ME, Benchimol EI et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2015; doi: 10.1002/14651858.CD000296.pub4.
6. Thomson O, Cortot A, Jewell DP et al. A comparison of budesonide and mesalamine for Crohn’s disease. International budesonide mesalamine study group. N Engl J Med 1998; 339: 370–374. doi: 10.1056/NEJM199808063390603.
7. Tromm J, Bunganič I, Tomsová E et al. Budesonide 9 mg is at least as effective as mesalamine 4.5g in patients with mildly to moderately active Crohn´s disease. Gastroenterology 2011; 140 (2): 425–434. doi: 10.1053/j.gastro.2010.11.004.
8. Kuenzig ME, Rezaie A, Seow CH et al. Budenoside for maintenance of remission in Crohn’s Disease. Cochrane Database Syst Rev 2017. doi: 10.1002/14651858.CD002913.pub3.
9. Travis SL, Danese S, Kapcinskas L et al. Once daily budesonide MMX in active mild to moderate ulcerative colitis“ results from the randomized CORE II study. Gut 2014; 63 (3): 433–441. doi: 10.1136/gutjnl-2012-304258.
10. Hrdlička L, Bortlík M, Douda T et al. Budesonid MMX (Cortiment 9 mg) v léčbě ulcerózní kolitidy v reálné klinické praxi. Gastroent Hepatol 2016; 70 (6): 509–513. doi: 10.14735/amgh2016509.
11. Gross V, Bar-Meir A, Lavy O et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther 2006; 23: 303–312. doi: 10.1111/j.1365-2036.2006.02 743.x.
12. Kafil TS, Nguyen TM, Patton PH et al. Intervention for treating collagenous colitis. Cochrane Database Syst Rev 217. doi: 10.1002/14651858.CD003575.pub6.
13. Reilev M, Hallas J, Ernst MT et al. Long-term oral budesonide treatment and risk of osteoporotic fractures in patients with microscopic colitis. Aliment Pharmacol Ther 2020; 51 (6): 644–651. doi: 10.1111/apt.15648.
Štítky
Paediatric gastroenterology Gastroenterology and hepatology SurgeryČlánok vyšiel v časopise
Gastroenterology and Hepatology
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Najčítanejšie v tomto čísle
- Proton pump inhibitors – do we know them well and are they really that safe? – part 1
- Budesonide in the treatment of idiopathic intestinal infl ammation
- New member of the editorial board MUDr. Kristýna Zárubová
- Predictors of advanced colorectal neoplasia in colorectal cancer screening – interim results of multicentric prospective study